English

REVANCE THERAPEUTICS, INC.

EDGAR

RVNC Quarterly report (10-Q) · filed 2024-11-07

96 filing records in this dataset, filed from 2013-12-31 to 2024-11-07. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

59.9 million USD

2024 Q3 · USD

Exact inputs and evidence

Revenue: 59879000 USD Source

Operating margin

-53.87%

2024 Q3 · %

Exact inputs and evidence

Operating Income: -32256000 USD Source
Revenue: 59879000 USD Source

Operating cash flow

-41.1 million USD

2024 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -148157000 USD Source
Operating Cash Flow: -107067000 USD Source

Free cash flow

-41.2 million USD

2024 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -148157000 USD Source
Operating Cash Flow: -107067000 USD Source
Capital Expenditure: 2243000 USD Source
Capital Expenditure: 2182000 USD Source

Cash and cash equivalents: 58.6 million USD 2024-09-30 Source
Exact value

58585000 USD
Long-term debt including current maturities: 431 million USD 2024-09-30 Source
Exact value

431191000 USD
Shares outstanding: 105 million shares 2024-09-30 Source
Exact value

104895611 shares

Reported share-count change

19.45% · 17.1 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

87813315 shares · 2023-09-30· Source
104895611 shares · 2024-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-185 million USD

2023-10-01 – 2024-09-30

Exact inputs and evidence

Net income: -324000000 USD · 2023-01-01 – 2023-12-31 Source
Net income: -268287000 USD · 2023-01-01 – 2023-09-30 Source
Net income: -53200000 USD · 2024-01-01 – 2024-03-31 Source
Net income: -37500000 USD · 2024-04-01 – 2024-06-30 Source
Net income: -38100000 USD · 2024-07-01 – 2024-09-30 Source

Operating cash flow

-191 million USD

2023-10-01 – 2024-09-30

Exact inputs and evidence

Operating cash flow: -216575000 USD · 2023-01-01 – 2023-12-31 Source
Operating cash flow: -173844000 USD · 2023-01-01 – 2023-09-30 Source
Operating cash flow: -65939000 USD · 2024-01-01 – 2024-03-31 Source
Operating cash flow: -107067000 USD · 2024-01-01 – 2024-06-30 Source
Operating cash flow: -65939000 USD · 2024-01-01 – 2024-03-31 Source
Operating cash flow: -148157000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: -107067000 USD · 2024-01-01 – 2024-06-30 Source

Capital expenditure

4.02 million USD

2023-10-01 – 2024-09-30

Exact inputs and evidence

Capital expenditure: 6886000 USD · 2023-01-01 – 2023-12-31 Source
Capital expenditure: 5107000 USD · 2023-01-01 – 2023-09-30 Source
Capital expenditure: 1712000 USD · 2024-01-01 – 2024-03-31 Source
Capital expenditure: 2182000 USD · 2024-01-01 – 2024-06-30 Source
Capital expenditure: 1712000 USD · 2024-01-01 – 2024-03-31 Source
Capital expenditure: 2243000 USD · 2024-01-01 – 2024-09-30 Source
Capital expenditure: 2182000 USD · 2024-01-01 – 2024-06-30 Source

Free cash flow

-195 million USD

2023-10-01 – 2024-09-30

Exact inputs and evidence

Operating cash flow: -216575000 USD · 2023-01-01 – 2023-12-31 Source
Operating cash flow: -173844000 USD · 2023-01-01 – 2023-09-30 Source
Operating cash flow: -65939000 USD · 2024-01-01 – 2024-03-31 Source
Operating cash flow: -107067000 USD · 2024-01-01 – 2024-06-30 Source
Operating cash flow: -65939000 USD · 2024-01-01 – 2024-03-31 Source
Operating cash flow: -148157000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: -107067000 USD · 2024-01-01 – 2024-06-30 Source
Capital expenditure: 6886000 USD · 2023-01-01 – 2023-12-31 Source
Capital expenditure: 5107000 USD · 2023-01-01 – 2023-09-30 Source
Capital expenditure: 1712000 USD · 2024-01-01 – 2024-03-31 Source
Capital expenditure: 2182000 USD · 2024-01-01 – 2024-06-30 Source
Capital expenditure: 1712000 USD · 2024-01-01 – 2024-03-31 Source
Capital expenditure: 2243000 USD · 2024-01-01 – 2024-09-30 Source
Capital expenditure: 2182000 USD · 2024-01-01 – 2024-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2024-11-07.

Financial data available through: 2023-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2023-12-31
Operating income: 11 of 11 periods available· newest 2023-12-31
Net income: 11 of 11 periods available· newest 2023-12-31
Operating cash flow: 11 of 11 periods available· newest 2023-12-31
Capital expenditure: 11 of 11 periods available· newest 2023-12-31
Total assets: 11 of 11 periods available· newest 2023-12-31
Total liabilities: 11 of 11 periods available· newest 2023-12-31
Current assets: 11 of 11 periods available· newest 2023-12-31
Current liabilities: 11 of 11 periods available· newest 2023-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2023-12-31
Long-term debt including current maturities: 3 of 11 periods available· newest 2023-12-31
Shares outstanding: 11 of 11 periods available· newest 2023-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+76.5%

Prior period

USD 132.57 million

2022-01-01 – 2022-12-31
Current period

USD 234.04 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

234040000 − 132565000 = 101475000 USD

132565000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
234040000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · REVANCE THERAPEUTICS, INC. · 2023-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Year-over-year change in Revenue: 101475000 USD Concept: fundies:Revenue Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 234040000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000038/rvnc-20231231.htm#2699156 Filing: 000147929024000038 Input fundies:Revenue: 132565000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000038/rvnc-20231231.htm#2700142 Filing: 000147929024000038
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 32.42 million

Prior period

−USD 356.42 million

2022-01-01 – 2022-12-31
Current period

−USD 324 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-324000000 − -356422000 = 32422000 USD

-356422000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-324000000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · REVANCE THERAPEUTICS, INC. · 2023-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Year-over-year change in Net income: 32422000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -324000000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000038/rvnc-20231231.htm#1860562 Filing: 000147929024000038 Input fundies:NetIncome: -356422000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000038/rvnc-20231231.htm#1770960 Filing: 000147929024000038
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 23.03 million

Prior period

−USD 193.55 million

2022-01-01 – 2022-12-31
Current period

−USD 216.58 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-216575000 − -193548000 = -23027000 USD

-193548000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-216575000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · REVANCE THERAPEUTICS, INC. · 2023-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Year-over-year change in Operating cash flow: -23027000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -216575000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000038/rvnc-20231231.htm#1807799 Filing: 000147929024000038 Input fundies:OperatingCashFlow: -193548000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000038/rvnc-20231231.htm#1808457 Filing: 000147929024000038
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+114.5%

Prior period

USD 3.21 million

2022-01-01 – 2022-12-31
Current period

USD 6.89 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

6886000 − 3210000 = 3676000 USD

3210000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
6886000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · REVANCE THERAPEUTICS, INC. · 2023-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Year-over-year change in Capital expenditure: 3676000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 6886000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000038/rvnc-20231231.htm#1814654 Filing: 000147929024000038 Input fundies:CapitalExpenditure: 3210000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000038/rvnc-20231231.htm#1815249 Filing: 000147929024000038
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2023 2023-01-01 – 2023-12-31

Revenue USD 234.04 million 100% of revenue
Operating costs Derived USD 550.82 million 235% of revenue
Operating income −USD 316.78 million −135% of revenue
Tax, interest and other Derived USD 7.22 million 3.1% of revenue
Net income −USD 324 million −138% of revenue

Cash

Operating cash flow −USD 216.58 million −93% of revenue
Capital expenditure USD 6.89 million 2.9% of revenue
Free cash flow Derived −USD 223.46 million −95% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2014 Operating loss: operating costs were 13,690% of revenue.
2015 Operating loss: operating costs were 24,206% of revenue.
2016 Operating loss: operating costs were 29,505% of revenue.
2017 Operating loss: operating costs were 46,063% of revenue.
2018 Operating loss: operating costs were 3,925% of revenue.
2019 Operating loss: operating costs were 39,921% of revenue.
2020 Operating loss: operating costs were 1,882% of revenue.
2021 Operating loss: operating costs were 453% of revenue.
2022 Operating loss: operating costs were 358% of revenue.
2023 Operating loss: operating costs were 235% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2014 2014-01-01 – 2014-12-31	383000	52433000 Derived	-52050000	10850000 Derived	-62900000	-62048000 Derived	Source 2014-01-01 – 2014-12-31: 383000 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -52050000 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -62900000 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: -55073000 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 6975000 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	300000	72617000 Derived	-72317000	1183000 Derived	-73500000	-58997000 Derived	Source 2015-01-01 – 2015-12-31: 300000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -72317000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -73500000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -55669000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 3328000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	300000	88515000 Derived	-88215000	1085000 Derived	-89300000	-61497000 Derived	Source 2016-01-01 – 2016-12-31: 300000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -88215000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -89300000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -59827000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 1670000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	262000	120686000 Derived	-120424000	163000 Derived	-120587000	-97867000 Derived	Source 2017-01-01 – 2017-12-31: 262000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -120424000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -120587000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -95342000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 2525000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	3729000	146363000 Derived	-142634000	-66000 Derived	-142568000	-111237000 Derived	Source 2018-01-01 – 2018-12-31: 3729000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -142634000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -142568000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -104246000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 6991000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	413000	164872000 Derived	-164459000	-5030000 Derived	-159429000	-109391000 Derived	Source 2019-01-01 – 2019-12-31: 413000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -164459000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -159429000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -106161000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 3230000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	15325000	288487000 Derived	-273162000	8927000 Derived	-282089000	-182600000 Derived	Source 2020-01-01 – 2020-12-31: 15325000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -273162000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -282089000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -178502000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 4098000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	77798000	352474000 Derived	-274676000	6634000 Derived	-281310000	-231913000 Derived	Source 2021-01-01 – 2021-12-31: 77798000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -274676000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -281310000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -221538000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 10375000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	132565000	474523000 Derived	-341958000	14464000 Derived	-356422000	-196758000 Derived	Source 2022-01-01 – 2022-12-31: 132565000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -341958000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -356422000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -193548000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 3210000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	234040000	550817000 Derived	-316777000	7223000 Derived	-324000000	-223461000 Derived	Source 2023-01-01 – 2023-12-31: 234040000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -316777000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -324000000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -216575000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 6886000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 234M 2023

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Revenue	383000	Revenue: 383000 Open source
20152015-12-31	Revenue	300000	Revenue: 300000 Open source
20162016-12-31	Revenue	300000	Revenue: 300000 Open source
20172017-12-31	Revenue	262000	Revenue: 262000 Open source
20182018-12-31	Revenue	3729000	Revenue: 3729000 Open source
20192019-12-31	Revenue	413000	Revenue: 413000 Open source
20202020-12-31	Revenue	15325000	Revenue: 15325000 Open source
20212021-12-31	Revenue	77798000	Revenue: 77798000 Open source
20222022-12-31	Revenue	132565000	Revenue: 132565000 Open source
20232023-12-31	Revenue	234040000	Revenue: 234040000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

76.5% 2023

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Year over year	-37.9%	Revenue: 383000 Open source Revenue: 617000 Open source
20152015-12-31	Year over year	-21.7%	Revenue: 300000 Open source Revenue: 383000 Open source
20162016-12-31	Year over year	0%	Revenue: 300000 Open source Revenue: 300000 Open source
20172017-12-31	Year over year	-12.7%	Revenue: 262000 Open source Revenue: 300000 Open source
20182018-12-31	Year over year	1,323.3%	Revenue: 3729000 Open source Revenue: 262000 Open source
20192019-12-31	Year over year	-88.9%	Revenue: 413000 Open source Revenue: 3729000 Open source
20202020-12-31	Year over year	3,610.7%	Revenue: 15325000 Open source Revenue: 413000 Open source
20212021-12-31	Year over year	407.7%	Revenue: 77798000 Open source Revenue: 15325000 Open source
20222022-12-31	Year over year	70.4%	Revenue: 132565000 Open source Revenue: 77798000 Open source
20232023-12-31	Year over year	76.5%	Revenue: 234040000 Open source Revenue: 132565000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -135.4% 2023

Net margin -138.4% 2023

Free cash flow margin -95.5% 2023

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Operating margin	-13,590.1%	Operating Income: -52050000 Open source Revenue: 383000 Open source
20152015-12-31	Operating margin	-24,105.7%	Operating Income: -72317000 Open source Revenue: 300000 Open source
20162016-12-31	Operating margin	-29,405%	Operating Income: -88215000 Open source Revenue: 300000 Open source
20172017-12-31	Operating margin	-45,963.4%	Operating Income: -120424000 Open source Revenue: 262000 Open source
20182018-12-31	Operating margin	-3,825%	Operating Income: -142634000 Open source Revenue: 3729000 Open source
20192019-12-31	Operating margin	-39,820.6%	Operating Income: -164459000 Open source Revenue: 413000 Open source
20202020-12-31	Operating margin	-1,782.5%	Operating Income: -273162000 Open source Revenue: 15325000 Open source
20212021-12-31	Operating margin	-353.1%	Operating Income: -274676000 Open source Revenue: 77798000 Open source
20222022-12-31	Operating margin	-258%	Operating Income: -341958000 Open source Revenue: 132565000 Open source
20232023-12-31	Operating margin	-135.4%	Operating Income: -316777000 Open source Revenue: 234040000 Open source
20142014-12-31	Net margin	-16,423%	Net Income: -62900000 Open source Revenue: 383000 Open source
20152015-12-31	Net margin	-24,500%	Net Income: -73500000 Open source Revenue: 300000 Open source
20162016-12-31	Net margin	-29,766.7%	Net Income: -89300000 Open source Revenue: 300000 Open source
20172017-12-31	Net margin	-46,025.6%	Net Income: -120587000 Open source Revenue: 262000 Open source
20182018-12-31	Net margin	-3,823.2%	Net Income: -142568000 Open source Revenue: 3729000 Open source
20192019-12-31	Net margin	-38,602.7%	Net Income: -159429000 Open source Revenue: 413000 Open source
20202020-12-31	Net margin	-1,840.7%	Net Income: -282089000 Open source Revenue: 15325000 Open source
20212021-12-31	Net margin	-361.6%	Net Income: -281310000 Open source Revenue: 77798000 Open source
20222022-12-31	Net margin	-268.9%	Net Income: -356422000 Open source Revenue: 132565000 Open source
20232023-12-31	Net margin	-138.4%	Net Income: -324000000 Open source Revenue: 234040000 Open source
20142014-12-31	Free cash flow margin	-16,200.5%	Revenue: 383000 Open source Operating Cash Flow: -55073000 Open source Capital Expenditure: 6975000 Open source
20152015-12-31	Free cash flow margin	-19,665.7%	Revenue: 300000 Open source Operating Cash Flow: -55669000 Open source Capital Expenditure: 3328000 Open source
20162016-12-31	Free cash flow margin	-20,499%	Revenue: 300000 Open source Operating Cash Flow: -59827000 Open source Capital Expenditure: 1670000 Open source
20172017-12-31	Free cash flow margin	-37,353.8%	Revenue: 262000 Open source Operating Cash Flow: -95342000 Open source Capital Expenditure: 2525000 Open source
20182018-12-31	Free cash flow margin	-2,983%	Revenue: 3729000 Open source Operating Cash Flow: -104246000 Open source Capital Expenditure: 6991000 Open source
20192019-12-31	Free cash flow margin	-26,486.9%	Revenue: 413000 Open source Operating Cash Flow: -106161000 Open source Capital Expenditure: 3230000 Open source
20202020-12-31	Free cash flow margin	-1,191.5%	Revenue: 15325000 Open source Operating Cash Flow: -178502000 Open source Capital Expenditure: 4098000 Open source
20212021-12-31	Free cash flow margin	-298.1%	Revenue: 77798000 Open source Operating Cash Flow: -221538000 Open source Capital Expenditure: 10375000 Open source
20222022-12-31	Free cash flow margin	-148.4%	Revenue: 132565000 Open source Operating Cash Flow: -193548000 Open source Capital Expenditure: 3210000 Open source
20232023-12-31	Free cash flow margin	-95.5%	Revenue: 234040000 Open source Operating Cash Flow: -216575000 Open source Capital Expenditure: 6886000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -216.6M 2023

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Operating cash flow	-55073000	Operating Cash Flow: -55073000 Open source
20152015-12-31	Operating cash flow	-55669000	Operating Cash Flow: -55669000 Open source
20162016-12-31	Operating cash flow	-59827000	Operating Cash Flow: -59827000 Open source
20172017-12-31	Operating cash flow	-95342000	Operating Cash Flow: -95342000 Open source
20182018-12-31	Operating cash flow	-104246000	Operating Cash Flow: -104246000 Open source
20192019-12-31	Operating cash flow	-106161000	Operating Cash Flow: -106161000 Open source
20202020-12-31	Operating cash flow	-178502000	Operating Cash Flow: -178502000 Open source
20212021-12-31	Operating cash flow	-221538000	Operating Cash Flow: -221538000 Open source
20222022-12-31	Operating cash flow	-193548000	Operating Cash Flow: -193548000 Open source
20232023-12-31	Operating cash flow	-216575000	Operating Cash Flow: -216575000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -223.5M 2023

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Free cash flow	-62048000	Operating Cash Flow: -55073000 Open source Capital Expenditure: 6975000 Open source
20152015-12-31	Free cash flow	-58997000	Operating Cash Flow: -55669000 Open source Capital Expenditure: 3328000 Open source
20162016-12-31	Free cash flow	-61497000	Operating Cash Flow: -59827000 Open source Capital Expenditure: 1670000 Open source
20172017-12-31	Free cash flow	-97867000	Operating Cash Flow: -95342000 Open source Capital Expenditure: 2525000 Open source
20182018-12-31	Free cash flow	-111237000	Operating Cash Flow: -104246000 Open source Capital Expenditure: 6991000 Open source
20192019-12-31	Free cash flow	-109391000	Operating Cash Flow: -106161000 Open source Capital Expenditure: 3230000 Open source
20202020-12-31	Free cash flow	-182600000	Operating Cash Flow: -178502000 Open source Capital Expenditure: 4098000 Open source
20212021-12-31	Free cash flow	-231913000	Operating Cash Flow: -221538000 Open source Capital Expenditure: 10375000 Open source
20222022-12-31	Free cash flow	-196758000	Operating Cash Flow: -193548000 Open source Capital Expenditure: 3210000 Open source
20232023-12-31	Free cash flow	-223461000	Operating Cash Flow: -216575000 Open source Capital Expenditure: 6886000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

131.7% 2023

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Liabilities / assets	8.4%	Total Liabilities: 16100000 Open source Total Assets: 192469000 Open source
20152015-12-31	Liabilities / assets	8.2%	Total Liabilities: 22570000 Open source Total Assets: 275822000 Open source
20162016-12-31	Liabilities / assets	13.4%	Total Liabilities: 27289000 Open source Total Assets: 204360000 Open source
20172017-12-31	Liabilities / assets	9.1%	Total Liabilities: 26854000 Open source Total Assets: 295699000 Open source
20182018-12-31	Liabilities / assets	35.7%	Total Liabilities: 80726000 Open source Total Assets: 226348000 Open source
20192019-12-31	Liabilities / assets	33.7%	Total Liabilities: 114797000 Open source Total Assets: 340287000 Open source
20202020-12-31	Liabilities / assets	48%	Total Liabilities: 345930000 Open source Total Assets: 720220000 Open source
20212021-12-31	Liabilities / assets	87.1%	Total Liabilities: 462692000 Open source Total Assets: 531163000 Open source
20222022-12-31	Liabilities / assets	97.8%	Total Liabilities: 569300000 Open source Total Assets: 581900000 Open source
20232023-12-31	Liabilities / assets	131.7%	Total Liabilities: 630058000 Open source Total Assets: 478454000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.8× 2023

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Current assets / current liabilities	16.87×	Current Assets: 172731000 Open source Current Liabilities: 10236000 Open source
20152015-12-31	Current assets / current liabilities	21.1×	Current Assets: 253963000 Open source Current Liabilities: 12037000 Open source
20162016-12-31	Current assets / current liabilities	9.81×	Current Assets: 192695000 Open source Current Liabilities: 19647000 Open source
20172017-12-31	Current assets / current liabilities	13.65×	Current Assets: 285211000 Open source Current Liabilities: 20902000 Open source
20182018-12-31	Current assets / current liabilities	6.5×	Current Assets: 207922000 Open source Current Liabilities: 31970000 Open source
20192019-12-31	Current assets / current liabilities	7.24×	Current Assets: 296602000 Open source Current Liabilities: 40979000 Open source
20202020-12-31	Current assets / current liabilities	7.38×	Current Assets: 450003000 Open source Current Liabilities: 60964000 Open source
20212021-12-31	Current assets / current liabilities	3.66×	Current Assets: 246117000 Open source Current Liabilities: 67289000 Open source
20222022-12-31	Current assets / current liabilities	4.95×	Current Assets: 374727000 Open source Current Liabilities: 75682000 Open source
20232023-12-31	Current assets / current liabilities	3.8×	Current Assets: 338865000 Open source Current Liabilities: 89224000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2014 2014-01-01 – 2014-12-31	−USD 62.9 million Exact value Exact value: -62900000 USD 2014-01-01 – 2014-12-31: -62900000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REVANCE THERAPEUTICS, INC. · 2014-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Net Income: -62900000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -62900000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929017000013/rvnc-20161231.xml#359465 Filing: 000147929017000013 The citation records this snapshot. The page link may show a newer release later.	−USD 55.07 million Exact value Exact value: -55073000 USD 2014-01-01 – 2014-12-31: -55073000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REVANCE THERAPEUTICS, INC. · 2014-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Operating Cash Flow: -55073000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -55073000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929017000013/rvnc-20161231.xml#358675 Filing: 000147929017000013 The citation records this snapshot. The page link may show a newer release later.	USD 6.98 million Exact value Exact value: 6975000 USD 2014-01-01 – 2014-12-31: 6975000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REVANCE THERAPEUTICS, INC. · 2014-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Capital Expenditure: 6975000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6975000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929017000013/rvnc-20161231.xml#377650 Filing: 000147929017000013 The citation records this snapshot. The page link may show a newer release later.	−USD 62.05 million Calculation and evidence -55073000 − 6975000 USD Exact free cash flow: -62048000 USD 2014-01-01 – 2014-12-31: -55073000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 6975000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REVANCE THERAPEUTICS, INC. · 2014-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Free cash flow: -62048000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -55073000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929017000013/rvnc-20161231.xml#358675 Filing: 000147929017000013 Input fundies:CapitalExpenditure: 6975000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929017000013/rvnc-20161231.xml#377650 Filing: 000147929017000013 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 73.5 million Exact value Exact value: -73500000 USD 2015-01-01 – 2015-12-31: -73500000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REVANCE THERAPEUTICS, INC. · 2015-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Net Income: -73500000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -73500000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929018000038/rvnc-20171231.xml#310126 Filing: 000147929018000038 The citation records this snapshot. The page link may show a newer release later.	−USD 55.67 million Exact value Exact value: -55669000 USD 2015-01-01 – 2015-12-31: -55669000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REVANCE THERAPEUTICS, INC. · 2015-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Operating Cash Flow: -55669000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -55669000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929018000038/rvnc-20171231.xml#309336 Filing: 000147929018000038 The citation records this snapshot. The page link may show a newer release later.	USD 3.33 million Exact value Exact value: 3328000 USD 2015-01-01 – 2015-12-31: 3328000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REVANCE THERAPEUTICS, INC. · 2015-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Capital Expenditure: 3328000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3328000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929018000038/rvnc-20171231.xml#330165 Filing: 000147929018000038 The citation records this snapshot. The page link may show a newer release later.	−USD 59 million Calculation and evidence -55669000 − 3328000 USD Exact free cash flow: -58997000 USD 2015-01-01 – 2015-12-31: -55669000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 3328000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REVANCE THERAPEUTICS, INC. · 2015-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Free cash flow: -58997000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -55669000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929018000038/rvnc-20171231.xml#309336 Filing: 000147929018000038 Input fundies:CapitalExpenditure: 3328000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929018000038/rvnc-20171231.xml#330165 Filing: 000147929018000038 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 89.3 million Exact value Exact value: -89300000 USD 2016-01-01 – 2016-12-31: -89300000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REVANCE THERAPEUTICS, INC. · 2016-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Net Income: -89300000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -89300000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929019000030/rvnc1231201810k.htm#1846489 Filing: 000147929019000030 The citation records this snapshot. The page link may show a newer release later.	−USD 59.83 million Exact value Exact value: -59827000 USD 2016-01-01 – 2016-12-31: -59827000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REVANCE THERAPEUTICS, INC. · 2016-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Operating Cash Flow: -59827000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -59827000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929019000030/rvnc1231201810k.htm#1770313 Filing: 000147929019000030 The citation records this snapshot. The page link may show a newer release later.	USD 1.67 million Exact value Exact value: 1670000 USD 2016-01-01 – 2016-12-31: 1670000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REVANCE THERAPEUTICS, INC. · 2016-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Capital Expenditure: 1670000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1670000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929019000030/rvnc1231201810k.htm#1774784 Filing: 000147929019000030 The citation records this snapshot. The page link may show a newer release later.	−USD 61.5 million Calculation and evidence -59827000 − 1670000 USD Exact free cash flow: -61497000 USD 2016-01-01 – 2016-12-31: -59827000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 1670000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REVANCE THERAPEUTICS, INC. · 2016-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Free cash flow: -61497000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -59827000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929019000030/rvnc1231201810k.htm#1770313 Filing: 000147929019000030 Input fundies:CapitalExpenditure: 1670000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929019000030/rvnc1231201810k.htm#1774784 Filing: 000147929019000030 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 120.59 million Exact value Exact value: -120587000 USD 2017-01-01 – 2017-12-31: -120587000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REVANCE THERAPEUTICS, INC. · 2017-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Net Income: -120587000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -120587000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000119312520164935/rvnc-20200331.xml#420264 Filing: 000119312520164935 The citation records this snapshot. The page link may show a newer release later.	−USD 95.34 million Exact value Exact value: -95342000 USD 2017-01-01 – 2017-12-31: -95342000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REVANCE THERAPEUTICS, INC. · 2017-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Operating Cash Flow: -95342000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -95342000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000119312520164935/rvnc-20200331.xml#428244 Filing: 000119312520164935 The citation records this snapshot. The page link may show a newer release later.	USD 2.53 million Exact value Exact value: 2525000 USD 2017-01-01 – 2017-12-31: 2525000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REVANCE THERAPEUTICS, INC. · 2017-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Capital Expenditure: 2525000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2525000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000119312520164935/rvnc-20200331.xml#429289 Filing: 000119312520164935 The citation records this snapshot. The page link may show a newer release later.	−USD 97.87 million Calculation and evidence -95342000 − 2525000 USD Exact free cash flow: -97867000 USD 2017-01-01 – 2017-12-31: -95342000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 2525000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REVANCE THERAPEUTICS, INC. · 2017-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Free cash flow: -97867000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -95342000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000119312520164935/rvnc-20200331.xml#428244 Filing: 000119312520164935 Input fundies:CapitalExpenditure: 2525000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000119312520164935/rvnc-20200331.xml#429289 Filing: 000119312520164935 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 142.57 million Exact value Exact value: -142568000 USD 2018-01-01 – 2018-12-31: -142568000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REVANCE THERAPEUTICS, INC. · 2018-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Net Income: -142568000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -142568000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929021000057/rvnc-20201231.htm#1745517 Filing: 000147929021000057 The citation records this snapshot. The page link may show a newer release later.	−USD 104.25 million Exact value Exact value: -104246000 USD 2018-01-01 – 2018-12-31: -104246000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REVANCE THERAPEUTICS, INC. · 2018-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Operating Cash Flow: -104246000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -104246000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929021000057/rvnc-20201231.htm#1803508 Filing: 000147929021000057 The citation records this snapshot. The page link may show a newer release later.	USD 6.99 million Exact value Exact value: 6991000 USD 2018-01-01 – 2018-12-31: 6991000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REVANCE THERAPEUTICS, INC. · 2018-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Capital Expenditure: 6991000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6991000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929021000057/rvnc-20201231.htm#1813750 Filing: 000147929021000057 The citation records this snapshot. The page link may show a newer release later.	−USD 111.24 million Calculation and evidence -104246000 − 6991000 USD Exact free cash flow: -111237000 USD 2018-01-01 – 2018-12-31: -104246000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 6991000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REVANCE THERAPEUTICS, INC. · 2018-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Free cash flow: -111237000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -104246000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929021000057/rvnc-20201231.htm#1803508 Filing: 000147929021000057 Input fundies:CapitalExpenditure: 6991000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929021000057/rvnc-20201231.htm#1813750 Filing: 000147929021000057 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 159.43 million Exact value Exact value: -159429000 USD 2019-01-01 – 2019-12-31: -159429000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REVANCE THERAPEUTICS, INC. · 2019-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Net Income: -159429000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -159429000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929022000034/rvnc-20211231.htm#1741366 Filing: 000147929022000034 The citation records this snapshot. The page link may show a newer release later.	−USD 106.16 million Exact value Exact value: -106161000 USD 2019-01-01 – 2019-12-31: -106161000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REVANCE THERAPEUTICS, INC. · 2019-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Operating Cash Flow: -106161000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -106161000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929022000034/rvnc-20211231.htm#1799512 Filing: 000147929022000034 The citation records this snapshot. The page link may show a newer release later.	USD 3.23 million Exact value Exact value: 3230000 USD 2019-01-01 – 2019-12-31: 3230000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REVANCE THERAPEUTICS, INC. · 2019-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Capital Expenditure: 3230000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3230000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929022000034/rvnc-20211231.htm#1806482 Filing: 000147929022000034 The citation records this snapshot. The page link may show a newer release later.	−USD 109.39 million Calculation and evidence -106161000 − 3230000 USD Exact free cash flow: -109391000 USD 2019-01-01 – 2019-12-31: -106161000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 3230000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REVANCE THERAPEUTICS, INC. · 2019-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Free cash flow: -109391000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -106161000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929022000034/rvnc-20211231.htm#1799512 Filing: 000147929022000034 Input fundies:CapitalExpenditure: 3230000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929022000034/rvnc-20211231.htm#1806482 Filing: 000147929022000034 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 282.09 million Exact value Exact value: -282089000 USD 2020-01-01 – 2020-12-31: -282089000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REVANCE THERAPEUTICS, INC. · 2020-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Net Income: -282089000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -282089000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929023000028/rvnc-20221231.htm#1943757 Filing: 000147929023000028 The citation records this snapshot. The page link may show a newer release later.	−USD 178.5 million Exact value Exact value: -178502000 USD 2020-01-01 – 2020-12-31: -178502000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REVANCE THERAPEUTICS, INC. · 2020-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Operating Cash Flow: -178502000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -178502000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929023000028/rvnc-20221231.htm#2008550 Filing: 000147929023000028 The citation records this snapshot. The page link may show a newer release later.	USD 4.1 million Exact value Exact value: 4098000 USD 2020-01-01 – 2020-12-31: 4098000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REVANCE THERAPEUTICS, INC. · 2020-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Capital Expenditure: 4098000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4098000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929023000028/rvnc-20221231.htm#2018690 Filing: 000147929023000028 The citation records this snapshot. The page link may show a newer release later.	−USD 182.6 million Calculation and evidence -178502000 − 4098000 USD Exact free cash flow: -182600000 USD 2020-01-01 – 2020-12-31: -178502000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 4098000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REVANCE THERAPEUTICS, INC. · 2020-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Free cash flow: -182600000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -178502000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929023000028/rvnc-20221231.htm#2008550 Filing: 000147929023000028 Input fundies:CapitalExpenditure: 4098000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929023000028/rvnc-20221231.htm#2018690 Filing: 000147929023000028 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 281.31 million Exact value Exact value: -281310000 USD 2021-01-01 – 2021-12-31: -281310000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REVANCE THERAPEUTICS, INC. · 2021-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Net Income: -281310000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -281310000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000038/rvnc-20231231.htm#1771745 Filing: 000147929024000038 The citation records this snapshot. The page link may show a newer release later.	−USD 221.54 million Exact value Exact value: -221538000 USD 2021-01-01 – 2021-12-31: -221538000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REVANCE THERAPEUTICS, INC. · 2021-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Operating Cash Flow: -221538000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -221538000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000038/rvnc-20231231.htm#1809116 Filing: 000147929024000038 The citation records this snapshot. The page link may show a newer release later.	USD 10.38 million Exact value Exact value: 10375000 USD 2021-01-01 – 2021-12-31: 10375000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REVANCE THERAPEUTICS, INC. · 2021-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Capital Expenditure: 10375000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 10375000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000038/rvnc-20231231.htm#1815845 Filing: 000147929024000038 The citation records this snapshot. The page link may show a newer release later.	−USD 231.91 million Calculation and evidence -221538000 − 10375000 USD Exact free cash flow: -231913000 USD 2021-01-01 – 2021-12-31: -221538000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 10375000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REVANCE THERAPEUTICS, INC. · 2021-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Free cash flow: -231913000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -221538000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000038/rvnc-20231231.htm#1809116 Filing: 000147929024000038 Input fundies:CapitalExpenditure: 10375000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000038/rvnc-20231231.htm#1815845 Filing: 000147929024000038 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 356.42 million Exact value Exact value: -356422000 USD 2022-01-01 – 2022-12-31: -356422000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REVANCE THERAPEUTICS, INC. · 2022-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Net Income: -356422000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -356422000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000038/rvnc-20231231.htm#1770960 Filing: 000147929024000038 The citation records this snapshot. The page link may show a newer release later.	−USD 193.55 million Exact value Exact value: -193548000 USD 2022-01-01 – 2022-12-31: -193548000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REVANCE THERAPEUTICS, INC. · 2022-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Operating Cash Flow: -193548000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -193548000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000038/rvnc-20231231.htm#1808457 Filing: 000147929024000038 The citation records this snapshot. The page link may show a newer release later.	USD 3.21 million Exact value Exact value: 3210000 USD 2022-01-01 – 2022-12-31: 3210000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REVANCE THERAPEUTICS, INC. · 2022-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Capital Expenditure: 3210000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3210000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000038/rvnc-20231231.htm#1815249 Filing: 000147929024000038 The citation records this snapshot. The page link may show a newer release later.	−USD 196.76 million Calculation and evidence -193548000 − 3210000 USD Exact free cash flow: -196758000 USD 2022-01-01 – 2022-12-31: -193548000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 3210000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REVANCE THERAPEUTICS, INC. · 2022-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Free cash flow: -196758000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -193548000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000038/rvnc-20231231.htm#1808457 Filing: 000147929024000038 Input fundies:CapitalExpenditure: 3210000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000038/rvnc-20231231.htm#1815249 Filing: 000147929024000038 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 324 million Exact value Exact value: -324000000 USD 2023-01-01 – 2023-12-31: -324000000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REVANCE THERAPEUTICS, INC. · 2023-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Net Income: -324000000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -324000000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000038/rvnc-20231231.htm#1860562 Filing: 000147929024000038 The citation records this snapshot. The page link may show a newer release later.	−USD 216.58 million Exact value Exact value: -216575000 USD 2023-01-01 – 2023-12-31: -216575000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REVANCE THERAPEUTICS, INC. · 2023-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Operating Cash Flow: -216575000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -216575000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000038/rvnc-20231231.htm#1807799 Filing: 000147929024000038 The citation records this snapshot. The page link may show a newer release later.	USD 6.89 million Exact value Exact value: 6886000 USD 2023-01-01 – 2023-12-31: 6886000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REVANCE THERAPEUTICS, INC. · 2023-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Capital Expenditure: 6886000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6886000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000038/rvnc-20231231.htm#1814654 Filing: 000147929024000038 The citation records this snapshot. The page link may show a newer release later.	−USD 223.46 million Calculation and evidence -216575000 − 6886000 USD Exact free cash flow: -223461000 USD 2023-01-01 – 2023-12-31: -216575000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 6886000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REVANCE THERAPEUTICS, INC. · 2023-12-31 REVANCE THERAPEUTICS, INC. (edgar:1479290) Free cash flow: -223461000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:33:58Z Snapshot: 3f70dfdf0ce60f2783135b2d892a04d7b3a08a90b5f3722c8fd41b0d2b3618ff Dimensions: Consolidated View: https://fundies.io/companies/edgar/1479290?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -216575000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000038/rvnc-20231231.htm#1807799 Filing: 000147929024000038 Input fundies:CapitalExpenditure: 6886000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000038/rvnc-20231231.htm#1814654 Filing: 000147929024000038 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

96 filings · 3,632 latest values · 3,632 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001479290, 1479290, RVNC, edgar:1479290

Also known as REVANCE THERAPEUTICS, INC., Revance Therapeutics, Inc.

REVANCE THERAPEUTICS, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2023 2023-01-01 – 2023-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation